A detailed history of Newman Dignan & Sheerar, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Newman Dignan & Sheerar, Inc. holds 17,258 shares of BMY stock, worth $917,953. This represents 0.19% of its overall portfolio holdings.

Number of Shares
17,258
Previous 20,395 15.38%
Holding current value
$917,953
Previous $1.11 Million 35.26%
% of portfolio
0.19%
Previous 0.3%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 15, 2024

SELL
$40.25 - $52.99 $126,264 - $166,229
-3,137 Reduced 15.38%
17,258 $716,000
Q1 2024

Apr 26, 2024

SELL
$47.98 - $54.4 $34,689 - $39,331
-723 Reduced 3.42%
20,395 $1.11 Million
Q4 2023

Feb 08, 2024

BUY
$48.48 - $57.85 $35,390 - $42,230
730 Added 3.58%
21,118 $1.08 Million
Q3 2023

Nov 07, 2023

SELL
$57.89 - $64.73 $58,237 - $65,118
-1,006 Reduced 4.7%
20,388 $1.18 Million
Q2 2023

Aug 02, 2023

BUY
$63.71 - $70.74 $191 - $212
3 Added 0.01%
21,394 $1.37 Million
Q1 2023

Apr 28, 2023

BUY
$65.71 - $74.53 $6,768 - $7,676
103 Added 0.48%
21,391 $1.48 Million
Q4 2022

Jan 20, 2023

BUY
$68.48 - $81.09 $29,583 - $35,030
432 Added 2.07%
21,288 $0
Q3 2022

Oct 18, 2022

BUY
$0.13 - $76.84 $17 - $10,450
136 Added 0.66%
20,856 $1.48 Million
Q2 2022

Aug 03, 2022

SELL
$72.62 - $79.98 $26,070 - $28,712
-359 Reduced 1.7%
20,720 $1.6 Million
Q1 2022

Apr 14, 2022

SELL
$61.48 - $73.72 $1,291 - $1,548
-21 Reduced 0.1%
21,079 $1.54 Million
Q4 2021

Jan 18, 2022

BUY
$53.63 - $62.52 $1,448 - $1,688
27 Added 0.13%
21,100 $1.32 Million
Q2 2021

Jul 28, 2021

BUY
$61.91 - $67.42 $70,082 - $76,319
1,132 Added 5.68%
21,073 $1.41 Million
Q1 2021

May 05, 2021

BUY
$59.34 - $66.74 $13,707 - $15,416
231 Added 1.17%
19,941 $1.26 Million
Q4 2020

Jan 29, 2021

BUY
$57.74 - $65.43 $8,661 - $9,814
150 Added 0.77%
19,710 $1.22 Million
Q3 2020

Oct 14, 2020

SELL
$57.43 - $63.64 $34,572 - $38,311
-602 Reduced 2.99%
19,560 $1.18 Million
Q2 2020

Aug 06, 2020

BUY
$54.82 - $64.09 $27,519 - $32,173
502 Added 2.55%
20,162 $1.19 Million
Q1 2020

Apr 20, 2020

SELL
$46.4 - $67.43 $36,656 - $53,269
-790 Reduced 3.86%
19,660 $1.17 Million
Q4 2019

Jan 15, 2020

SELL
$49.21 - $64.19 $30,510 - $39,797
-620 Reduced 2.94%
20,450 $1.31 Million
Q3 2019

Oct 21, 2019

SELL
$42.77 - $50.71 $173,132 - $205,274
-4,048 Reduced 16.12%
21,070 $1.07 Million
Q2 2019

Jul 31, 2019

SELL
$44.62 - $49.34 $23,648 - $26,150
-530 Reduced 2.07%
25,118 $1.14 Million
Q1 2019

Apr 09, 2019

SELL
$45.12 - $53.8 $65,694 - $78,332
-1,456 Reduced 5.37%
25,648 $1.22 Million
Q4 2018

Jan 24, 2019

SELL
$48.76 - $63.23 $8,142 - $10,559
-167 Reduced 0.61%
27,104 $1.41 Million
Q3 2018

Oct 25, 2018

BUY
$55.19 - $62.25 $662 - $747
12 Added 0.04%
27,271 $1.7 Million
Q2 2018

Jul 06, 2018

SELL
$50.53 - $62.98 $102,676 - $127,975
-2,032 Reduced 6.94%
27,259 $1.51 Million
Q1 2018

Apr 17, 2018

SELL
$59.92 - $68.98 $81,431 - $93,743
-1,359 Reduced 4.43%
29,291 $1.72 Million
Q4 2017

Jan 29, 2018

SELL
$59.94 - $65.35 $43,096 - $46,986
-719 Reduced 2.29%
30,650 $1.88 Million
Q3 2017

Oct 18, 2017

SELL
$55.23 - $63.74 $49,983 - $57,684
-905 Reduced 2.8%
31,369 $2 Million
Q2 2017

Aug 08, 2017

BUY
N/A
32,274
32,274 $1.8 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Newman Dignan & Sheerar, Inc. Portfolio

Follow Newman Dignan & Sheerar, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newman Dignan & Sheerar, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newman Dignan & Sheerar, Inc. with notifications on news.